{"id":"fosamprenavir-ritonavir","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Rash"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"20-30","effect":"Lipid abnormalities"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosamprenavir is a prodrug that is converted to amprenavir, which inhibits HIV protease and prevents the cleavage of viral polyproteins necessary for infectious particle maturation. Ritonavir is a potent CYP3A4 inhibitor that dramatically increases fosamprenavir plasma concentrations, allowing for lower and less frequent dosing while maintaining therapeutic efficacy.","oneSentence":"Fosamprenavir is a protease inhibitor that blocks HIV protease, preventing viral replication, while ritonavir acts as a pharmacokinetic booster to increase fosamprenavir levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:52.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT00071760","phase":"PHASE2","title":"Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2003-10-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":59},{"nctId":"NCT00028366","phase":"NA","title":"Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00027339","phase":"PHASE2","title":"Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT00977301","phase":"PHASE1","title":"Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-11","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00817765","phase":"PHASE1","title":"Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-01","conditions":"HIV Infection, Fungal Infection","enrollment":24},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT00094523","phase":"PHASE3","title":"Fosamprenavir Versus Other Protease Inhibitors","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-12-14","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":314},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44},{"nctId":"NCT01077635","phase":"","title":"PENTA Fosamprenavir Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2008-10","conditions":"Infection, Human Immunodeficiency Virus","enrollment":1},{"nctId":"NCT00242840","phase":"PHASE3","title":"Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2003-06","conditions":"Infection, Human Immunodeficiency Virus I, HIV Infection","enrollment":20},{"nctId":"NCT00089583","phase":"PHASE2","title":"48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-07","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":110},{"nctId":"NCT00040664","phase":"PHASE2","title":"A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2002-07","conditions":"HIV Infection","enrollment":69},{"nctId":"NCT01209065","phase":"PHASE1","title":"GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-09","conditions":"Infections, Human Immunodeficiency Virus and Herpesviridae","enrollment":27},{"nctId":"NCT01348308","phase":"PHASE3","title":"Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-09","conditions":"HIV-1 Infection, AIDS","enrollment":407},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00764465","phase":"PHASE2","title":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-10","conditions":"Healthy","enrollment":45},{"nctId":"NCT00802074","phase":"NA","title":"An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-12","conditions":"Healthy","enrollment":45},{"nctId":"NCT00614991","phase":"NA","title":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT01585753","phase":"","title":"MARCH Vascular Endothelium Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Cardiovascular Disease","enrollment":34},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT01222611","phase":"PHASE4","title":"HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2011-03","conditions":"Chronic HIV Infection, HCV Coinfection","enrollment":42},{"nctId":"NCT00877591","phase":"PHASE1","title":"Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-04","conditions":"Opioid Dependency, HIV Infections","enrollment":63},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00242216","phase":"PHASE4","title":"\"The Once A Day Protease Inhibitor Regimens\"","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2004-05","conditions":"HIV Infections","enrollment":76},{"nctId":"NCT00148785","phase":"PHASE4","title":"A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-07","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00727597","phase":"PHASE3","title":"A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infections","enrollment":101},{"nctId":"NCT00335270","phase":"PHASE4","title":"A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-03","conditions":"HIV","enrollment":100},{"nctId":"NCT00296504","phase":"PHASE3","title":"A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2001-11","conditions":"Infection, Human Immunodeficiency Virus","enrollment":753},{"nctId":"NCT00043888","phase":"PHASE3","title":"Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-01","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00966329","phase":"PHASE4","title":"Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-10","conditions":"HIV, HIV Infections","enrollment":30},{"nctId":"NCT00884793","phase":"NA","title":"Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-09","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00450580","phase":"PHASE3","title":"HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2007-03","conditions":"Infection, Human Immunodeficiency Virus I, HIV-1 Infection","enrollment":212},{"nctId":"NCT01010399","phase":"PHASE4","title":"Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects","status":"COMPLETED","sponsor":"Felizarta, Franco, M.D.","startDate":"2009-09","conditions":"Hypertriglyceridemia, HIV Infection","enrollment":36},{"nctId":"NCT00122603","phase":"PHASE2","title":"Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2005-12","conditions":"HIV Infections","enrollment":61},{"nctId":"NCT01290211","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-04","conditions":"Healthy","enrollment":28},{"nctId":"NCT00085943","phase":"PHASE3","title":"KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":"HIV Infection, Infection, Human Immunodeficiency Virus","enrollment":866},{"nctId":"NCT01140412","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-07","conditions":"Healthy","enrollment":14},{"nctId":"NCT00775125","phase":"PHASE1","title":"VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-06","conditions":"Hepatitis C, Telaprevir, HIV","enrollment":40},{"nctId":"NCT00363142","phase":"PHASE3","title":"A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"HIV Infection, Infection, Human Immunodeficiency Virus","enrollment":211},{"nctId":"NCT00481182","phase":"PHASE1","title":"Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT00144833","phase":"PHASE3","title":"Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"HIV-1","enrollment":150},{"nctId":"NCT00025727","phase":"PHASE3","title":"Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure","status":"UNKNOWN","sponsor":"GlaxoSmithKline","startDate":"2001-05","conditions":"HIV Infections","enrollment":330},{"nctId":"NCT00009061","phase":"PHASE3","title":"Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs","status":"UNKNOWN","sponsor":"Glaxo Wellcome","startDate":"2000-11","conditions":"HIV Infections","enrollment":624}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"THROMBOCYTOPENIA"},{"count":6,"reaction":"HYPERSPLENISM"},{"count":6,"reaction":"INTERVERTEBRAL DISC PROTRUSION"},{"count":6,"reaction":"NODULAR REGENERATIVE HYPERPLASIA"},{"count":6,"reaction":"PORTAL HYPERTENSION"},{"count":6,"reaction":"PORTAL VEIN THROMBOSIS"},{"count":6,"reaction":"VARICES OESOPHAGEAL"},{"count":3,"reaction":"DRUG INTERACTION"},{"count":3,"reaction":"HEPATOTOXICITY"},{"count":3,"reaction":"THERAPY NON-RESPONDER"}],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lexiva/Norvir"],"phase":"marketed","status":"active","brandName":"Fosamprenavir/ritonavir","genericName":"Fosamprenavir/ritonavir","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosamprenavir is a protease inhibitor that blocks HIV protease, preventing viral replication, while ritonavir acts as a pharmacokinetic booster to increase fosamprenavir levels. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}